Pandey Purneshwar Kumar, Swami Abhijit, Biswas Tanuj Kumar, Thakuria Riturag
Silchar Medical College and Hospital, Department of Medicine, Silchar, India.
Arch Rheumatol. 2016 Oct 13;32(1):46-52. doi: 10.5606/ArchRheumatol.2017.5949. eCollection 2017 Mar.
This study aims to assess the prevalence of metabolic syndrome (MetS) in treatment naïve rheumatoid arthritis (RA) in an Indian population and correlate RA disease characteristics with presence of MetS.
The study included 84 RA patients (18 males, 66 females; mean age 44.8±12.5 years; range 18 to 72 years) diagnosed according to 2010 American College of Rheumatology-European League Against Rheumatism classification criteria who were treatment naïve or did not receive disease modifying antirheumatic drugs for more than six weeks and 120 age and sex-matched apparently healthy controls (35 males, 85 females; mean age 44.1±12.7 years; range 18 to 75 years). The frequency of MetS was assessed using National Cholesterol Education Program- Adult Treatment Panel III 2004 revised criteria. Patients were also assessed in terms of disease activity, using disease activity score 28 erythrocyte sedimentation rate. Logistic regression was used to identify predictors of MetS in RA.
Metabolic syndrome was found in 39.28% of RA group and 20% of control group according to National Cholesterol Education Program- Adult Treatment Panel III 2004 (p<0.005). MetS was most commonly detected in the 51 to 60 age group (65%). RA group was significantly more likely to have low high-density lipoprotein (63.09%), high triglyceride (53.57%), elevated blood pressure (41.66%) levels, and elevated waist circumference (38.09%). In RA group, disease activity score 28 (odds ratio: 6.51, confidence interval: 1.19-35.46 p=0.03), C-reactive protein (odds ratio: 1.13, confidence interval: 1.05-1.21 p<0.001), and duration of disease (odds ratio: 1.82, confidence interval: 1.04-3.18 p=0.03) remained independent predictors for presence of MetS in RA.
The frequency of MetS was higher in RA group compared to control group. Higher systemic inflammatory marker, disease duration, and disease activity score 28 remained independent predictors associated with presence of MetS. These findings suggest that RA patients should be screened early for presence of MetS to check for and reduce risk of atherosclerotic vascular diseases.
本研究旨在评估印度人群中初治类风湿关节炎(RA)患者代谢综合征(MetS)的患病率,并将RA疾病特征与MetS的存在进行关联。
该研究纳入了84例根据2010年美国风湿病学会-欧洲抗风湿病联盟分类标准诊断的RA患者(18例男性,66例女性;平均年龄44.8±12.5岁;年龄范围18至72岁),这些患者为初治患者或未接受改善病情抗风湿药物治疗超过六周,以及120例年龄和性别匹配的明显健康对照者(35例男性,85例女性;平均年龄44.1±12.7岁;年龄范围18至75岁)。采用2004年美国国家胆固醇教育计划成人治疗小组第三次修订标准评估MetS的发生率。还使用疾病活动评分28红细胞沉降率对患者的疾病活动情况进行评估。采用逻辑回归分析确定RA患者中MetS的预测因素。
根据2004年美国国家胆固醇教育计划成人治疗小组第三次修订标准,RA组中39.28%的患者存在代谢综合征,对照组中这一比例为20%(p<0.005)。MetS最常见于51至60岁年龄组(65%)。RA组更易出现低高密度脂蛋白(63.09%)、高甘油三酯(53.57%)、血压升高(41.66%)以及腰围增加(38.09%)。在RA组中,疾病活动评分28(比值比:6.51,置信区间:1.19 - 35.46,p = 0.03)、C反应蛋白(比值比:1.13,置信区间:1.05 - 1.21,p<0.001)以及疾病持续时间(比值比:1.82,置信区间:1.04 - 3.18,p = 0.03)仍然是RA患者存在MetS的独立预测因素。
与对照组相比,RA组中MetS的发生率更高。较高的全身炎症标志物、疾病持续时间以及疾病活动评分28仍然是与MetS存在相关的独立预测因素。这些发现表明,应尽早对RA患者进行MetS筛查,以检查并降低动脉粥样硬化性血管疾病的风险。